Cytosorbents Crp Stock Performance
| CTSO Stock | USD 0.97 0.06 6.59% |
Cytosorbents Crp has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.14, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytosorbents Crp will likely underperform. Cytosorbents Crp right now shows a risk of 6.22%. Please confirm Cytosorbents Crp value at risk, as well as the relationship between the skewness and day median price , to decide if Cytosorbents Crp will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Cytosorbents Crp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Cytosorbents Crp may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
Last Split Factor 1:25 | Last Split Date 2014-12-05 |
1 | Acquisition by Bator Michael G. of 1000 shares of Cytosorbents Crp at 3.2 subject to Rule 16b-3 | 09/06/2024 |
2 | Cytosorbents shareholders have endured a 81 percent loss from investing in the stock three years ago | 09/30/2024 |
3 | CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Tic... | 10/01/2024 |
4 | Acquisition by Capponi Vincent of 50000 shares of Cytosorbents Crp at 1.19 subject to Rule 16b-3 | 10/04/2024 |
5 | Acquisition by Chan Phillip P. of 240000 shares of Cytosorbents Crp subject to Rule 16b-3 | 10/07/2024 |
6 | CytoSorbents Corp Q2 2024 Earnings Call Highlights Revenue Growth and Strategic ... | 10/09/2024 |
7 | FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review | 10/22/2024 |
8 | Cytosorbents Q3 2024 Earnings Preview | 11/06/2024 |
9 | CytoSorbents Q3 Earnings Snapshot | 11/07/2024 |
10 | CytoSorbents Corp Q3 2024 Earnings Call Highlights Strong Sales Growth and Improved ... | 11/08/2024 |
11 | Granahan Investment Management Reduces Stake in CytoSorbents Cor - GuruFocus.com | 11/15/2024 |
12 | Acquisition by Chan Phillip P. of 129998 shares of Cytosorbents Crp at 0.95 subject to Rule 16b-3 | 11/27/2024 |
| Begin Period Cash Flow | 23.8 M |
Cytosorbents |
Cytosorbents Crp Relative Risk vs. Return Landscape
If you would invest 102.00 in Cytosorbents Crp on September 2, 2024 and sell it today you would lose (5.00) from holding Cytosorbents Crp or give up 4.9% of portfolio value over 90 days. Cytosorbents Crp is currently generating 0.1079% in daily expected returns and assumes 6.2221% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Cytosorbents, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytosorbents Crp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytosorbents Crp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytosorbents Crp, and traders can use it to determine the average amount a Cytosorbents Crp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0173
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | CTSO | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.22 actual daily | 55 55% of assets are less volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Cytosorbents Crp is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytosorbents Crp by adding it to a well-diversified portfolio.
Cytosorbents Crp Fundamentals Growth
Cytosorbents Stock prices reflect investors' perceptions of the future prospects and financial health of Cytosorbents Crp, and Cytosorbents Crp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytosorbents Stock performance.
| Return On Equity | -1.18 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (0.46) % | ||||
| Current Valuation | 74.16 M | ||||
| Shares Outstanding | 54.68 M | ||||
| Price To Earning | (16.30) X | ||||
| Price To Book | 4.08 X | ||||
| Price To Sales | 1.41 X | ||||
| Revenue | 36.35 M | ||||
| Gross Profit | 20.73 M | ||||
| EBITDA | (28.81 M) | ||||
| Net Income | (28.51 M) | ||||
| Cash And Equivalents | 30.16 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 18.31 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Earnings Per Share | (0.36) X | ||||
| Market Capitalization | 53.04 M | ||||
| Total Asset | 53.26 M | ||||
| Retained Earnings | (282.51 M) | ||||
| Working Capital | 11.16 M | ||||
| Current Asset | 9.05 M | ||||
| Current Liabilities | 5 M | ||||
About Cytosorbents Crp Performance
By examining Cytosorbents Crp's fundamental ratios, stakeholders can obtain critical insights into Cytosorbents Crp's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cytosorbents Crp is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 96.24 | 91.43 | |
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.81) | (0.77) | |
| Return On Assets | (0.54) | (0.56) | |
| Return On Equity | (1.22) | (1.16) |
Things to note about Cytosorbents Crp performance evaluation
Checking the ongoing alerts about Cytosorbents Crp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytosorbents Crp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytosorbents Crp had very high historical volatility over the last 90 days | |
| Cytosorbents Crp has some characteristics of a very speculative penny stock | |
| Cytosorbents Crp has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 36.35 M. Net Loss for the year was (28.51 M) with profit before overhead, payroll, taxes, and interest of 20.73 M. | |
| Cytosorbents Crp currently holds about 30.16 M in cash with (21.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69. | |
| Cytosorbents Crp has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Granahan Investment Management Reduces Stake in CytoSorbents Cor - GuruFocus.com |
- Analyzing Cytosorbents Crp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytosorbents Crp's stock is overvalued or undervalued compared to its peers.
- Examining Cytosorbents Crp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytosorbents Crp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytosorbents Crp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytosorbents Crp's stock. These opinions can provide insight into Cytosorbents Crp's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.36) | Revenue Per Share 0.72 | Quarterly Revenue Growth 0.066 | Return On Assets (0.28) | Return On Equity (1.19) |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.